共 50 条
- [21] ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), for the treatment of first-line metastatic triple negative breast cancer (mTNBC).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Ma, FeiQiu, FumingTong, ZhongshengShi, YehuiYu, GuohuaWu, XinhongWang, HongWang, JianiYang, HuaLiu, AnwenZhang, YanZheng, HongmeiLan, QiongyuZhang, YongqiangCheng, YingZhou, QingXing, XiaoyanChen, Xiaomei
- [22] Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2141 - +Bardia, AdityaMayer, Ingrid A.Diamond, Jennifer R.Moroose, Rebecca L.Isakoff, Steven J.Starodub, Alexander N.Shah, Nikita C.O'Shaughnessy, JoyceKalinsky, KevinGuarino, MichaelAbramson, VandanaJuric, DejanTolaney, Sara M.Berlin, JordanMessersmith, Wells A.Ocean, Allyson J.Wegener, William A.Maliakal, PiusSharkey, Robert M.Govindan, Serengulam V.Goldenberg, David M.Vahdat, Linda T.
- [23] hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic CancerJOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (21) : 14700 - 14715Sun, Li-pingBai, Wei-qiZhou, Dan-danWu, Xiao-fanZhang, Lan-wenCui, A-longXie, Zi-huiGao, Rui-juanZhen, Yong-suLi, Zhuo-RongMiao, Qing-fang
- [24] SHR-A1921, A TROP-2 Targeted Antibody-Drug Conjugate (ADC), In Patients (pts) with Advanced Small-Cell Lung Cancer (SCLC)JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S16 - S17Wang, J.Wu, L.Li, X.Xing, N.Zhang, S.Song, Z.Chen, L.Dang, Q.Liu, C.Li, Y.Xu, H.Zhong, J.Wu, Y.Lin, Z.Zhang, Z.Wang, S.
- [25] Results from a phase Ia/Ib Study of ESG401, a novel Trop2 antibody-drug conjugate, in patients with different subtypes of metastatic breast cancerANNALS OF ONCOLOGY, 2024, 35 : S361 - S362Ma, F.Qiu, F.Tong, Z.Wang, J.Shi, Y.Zhang, Y.Yu, G.Shi, H.Wu, X.Liu, A.Zhang, Y.Wang, H.Cheng, Y.Yang, H.Li, H.Chang, J.Xing, X.
- [26] Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132) in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Starodub, AlexanderCamidge, D. RossScheff, Ronald J.Thomas, Sajeve SamuelGuarino, Michael J.Masters, Gregory A.Kalinsky, KevinGandhi, LeenaBardia, AdityaMessersmith, Wells A.Ocean, Allyson J.Maliakal, Pius P.Sharkey, Robert M.Wilhelm, FrancoisGoldenberg, David M.Heist, Rebecca Suk
- [27] RN927C, a potent site-specific Trop-2 antibody-drug-conjugate (ADC) for treatment of solid tumorsCANCER RESEARCH, 2014, 74 (19)Liu, Shu-HuiStrop, PavelThomas-Toan TranDorywalska, MagdalenaDelaria, KatherineHo, Wei-HsienDushin, RussellPons, JaumeRajpal, ArvindShelton, Dave
- [28] Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLCANNALS OF ONCOLOGY, 2020, 31 : S1189 - S1190Yu, H. A.Baik, C. S.Gold, K.Hayashi, H.Johnson, M.Koczywas, M.Murakami, H.Nishio, M.Steuer, C.Su, W-C.Yang, J.Karam, S.Qi, Z.Qiu, Y.Chen, S.Yu, C.Janne, P. A.
- [29] EFFICACY AND ADDITIONAL MECHANISM OF ACTION OF SACITUZUMAB GOVITECAN, A TROP-2 DIRECTED ANTIBODY-DRUG CONJUGATE, IN PRECLINICAL MODELS OF NON-MUSCLE INVASIVE BLADDER CANCERJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1262 - A1262Chou, Chih-ChienKornyeyev, DmytroYang, BeckyOrf, JessicaSun, Hai-LingDave, RutwijLai, YurongPapalia, GiuseppeCardillo, ThomasScholler, Nathalie
- [30] IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Trop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Starodub, AlexanderOcean, Allyson J.Guarino, Michael J.Picozzi, Vincent J.Thomas, Salim SamuelMessersmith, Wells A.Shah, Manlsh A.Vandat, Linda T.Chuang, EllenLin, Bruce S.Govindan, Serengulam V.Maliakal, Pius P.Wegener, William A.Hamburger, Steven A.Sharkey, Robert M.Goldenberg, David M.